Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Next Previous
Trial Profile

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epcoritamab (Primary) ; Anakinra; Bendamustine; Buclizine; Gemcitabine; Oxaliplatin; Rituximab; Tocilizumab
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EPCORE DLBCL-1; EPCORE&TRADE
  • Sponsors Genmab

Most Recent Events

  • 23 Jul 2026 According to a Genmab media release, additional results of the EPCORE DLBCL-1 study will be submitted for publication in a peer-reviewed medical journal.
  • 23 Jul 2026 According to a Genmab media release, primary endpoint (Overall Survival (OS)) has not been met.
  • 23 Jul 2026 According to a Genmab media release, data from this study presented at the European Hematology Association (EHA) 2026 Congress on June 12, 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top